JP7869804B2 - 新規のDARPinに基づくCD33エンゲージャ - Google Patents

新規のDARPinに基づくCD33エンゲージャ

Info

Publication number
JP7869804B2
JP7869804B2 JP2023554812A JP2023554812A JP7869804B2 JP 7869804 B2 JP7869804 B2 JP 7869804B2 JP 2023554812 A JP2023554812 A JP 2023554812A JP 2023554812 A JP2023554812 A JP 2023554812A JP 7869804 B2 JP7869804 B2 JP 7869804B2
Authority
JP
Japan
Prior art keywords
ankyrin repeat
binding
protein
amino acid
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023554812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024508969A (ja
JP2024508969A5 (cg-RX-API-DMAC7.html
Inventor
ニーナ レシュケ
クリスティアン ライヒェン
ベルント シュレーレス
Original Assignee
モレキュラー パートナーズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー パートナーズ アクチェンゲゼルシャフト filed Critical モレキュラー パートナーズ アクチェンゲゼルシャフト
Publication of JP2024508969A publication Critical patent/JP2024508969A/ja
Publication of JP2024508969A5 publication Critical patent/JP2024508969A5/ja
Application granted granted Critical
Publication of JP7869804B2 publication Critical patent/JP7869804B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ignition Installations For Internal Combustion Engines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Electroluminescent Light Sources (AREA)
JP2023554812A 2021-03-09 2022-03-09 新規のDARPinに基づくCD33エンゲージャ Active JP7869804B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163158539P 2021-03-09 2021-03-09
US63/158,539 2021-03-09
US202163172818P 2021-04-09 2021-04-09
US63/172,818 2021-04-09
US202163265179P 2021-12-09 2021-12-09
US63/265,179 2021-12-09
PCT/IB2022/052120 WO2022190010A1 (en) 2021-03-09 2022-03-09 Novel darpin based cd33 engagers

Publications (3)

Publication Number Publication Date
JP2024508969A JP2024508969A (ja) 2024-02-28
JP2024508969A5 JP2024508969A5 (cg-RX-API-DMAC7.html) 2025-03-18
JP7869804B2 true JP7869804B2 (ja) 2026-06-03

Family

ID=80933410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023554812A Active JP7869804B2 (ja) 2021-03-09 2022-03-09 新規のDARPinに基づくCD33エンゲージャ

Country Status (6)

Country Link
US (1) US20240317852A1 (cg-RX-API-DMAC7.html)
EP (1) EP4304730A1 (cg-RX-API-DMAC7.html)
JP (1) JP7869804B2 (cg-RX-API-DMAC7.html)
AU (1) AU2022231913A1 (cg-RX-API-DMAC7.html)
CA (1) CA3211248A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022190010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
WO2024251628A1 (en) * 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025163082A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513370A (ja) 2009-12-09 2013-04-22 フリードリヒ−アレクサンダー−ウニベルジテート・エアランゲン−ニュルンベルク 急性骨髄性白血病に対する三重特異性治療剤
JP2014501509A (ja) 2010-11-26 2014-01-23 モレキュラー・パートナーズ・アーゲー 血清アルブミンに結合する設計リピートタンパク質

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
US20050048512A1 (en) 2001-04-26 2005-03-03 Avidia Research Institute Combinatorial libraries of monomer domains
US20040175756A1 (en) 2001-04-26 2004-09-09 Avidia Research Institute Methods for using combinatorial libraries of monomer domains
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
SG11201408196RA (en) 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US9458211B1 (en) 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
MY196882A (en) 2016-09-22 2023-05-08 Molecular Partners Ag Recombinant binding proteins and their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013513370A (ja) 2009-12-09 2013-04-22 フリードリヒ−アレクサンダー−ウニベルジテート・エアランゲン−ニュルンベルク 急性骨髄性白血病に対する三重特異性治療剤
JP2014501509A (ja) 2010-11-26 2014-01-23 モレキュラー・パートナーズ・アーゲー 血清アルブミンに結合する設計リピートタンパク質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
mAbs,2017年10月31日,2017, VOL. 9, NO. 8,1262-1269

Also Published As

Publication number Publication date
US20240317852A1 (en) 2024-09-26
AU2022231913A1 (en) 2023-09-28
CA3211248A1 (en) 2022-09-15
EP4304730A1 (en) 2024-01-17
JP2024508969A (ja) 2024-02-28
AU2022231913A9 (en) 2024-01-25
WO2022190010A1 (en) 2022-09-15

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260522

R150 Certificate of patent or registration of utility model

Ref document number: 7869804

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150